Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells, directed against a tumor-associated antigen. Extracellular vesicles (EVs) derived from CAR-T cells (CAR-T EVs) may preserve CAR-T activity and overcome one of the major obstacles responsible for CAR-T cell failure in patients with solid tumors. This study aimed to compare CAR-T EVs with their parental cells and explore their cell penetration and cytotoxic activity. Anti-HER-2 CARs were stimulated with specific target cells. EVs were isolated from the cell media and characterized for their content and functions. We found that CAR-T EVs contained a mixture of small and large EVs. Stimulated anti-HER-2+ CAR-T EVs expressed lower cytokine levels compared with their parental CAR-T cells (such as interferon gamma). Higher levels of granzyme B were found in CAR-T EVs (≥20 × ) compared with EVs from unstimulated cells (p < 0.001). Anti-HER-2+ CAR-T EVs bound and penetrated specifically into HER-2 expressing target cells. Similar cytotoxic effects measured by caspase-3/7 activity were found in CAR-T cells and their derived EVs. However, while the CAR-T cells induced massive apoptosis during the first 24 h, CAR-T EVs required 60 − 90 h. In summary, CAR-T EVs provide a novel potent immunotherapy approach that may be effective against solid tumors.
Get full access to this article
View all access options for this article.
References
1.
HirayamaAV, GauthierJ, HayKA, et al.High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood, 2019; 134:636–640.
2.
WangM, MunozJ, GoyA, et al.KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med, 2020; 382:1331–1342.
3.
MunshiNC, AndersonLDJr., ShahN, et al.Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med, 2021; 384:705–716.
4.
MarofiF, MotavalliR, SafonovVA, et al.CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther, 2021; 12:81.
5.
HayKA, HanafiLA, LiD, et al.Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood, 2017; 130:2295–2306.
6.
WeiJ, LiuY, WangC, et al.The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther, 2020; 5:134.
7.
RussellAE, SneiderA, WitwerKW, et al.Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: an ISEV position paper arising from the ISEV membranes and EVs workshop. J Extracell Vesicles, 2019; 8:1684862.
8.
AharonA, SpectorP, AhmadRS, et al.Extracellular vesicles of Alzheimer's disease patients as a biomarker for disease progression. Mol Neurobiol, 2020; 57:4156–4169.
9.
AvisarA, CohenM, BrennerB, et al.Extracellular vesicles reflect the efficacy of wheatgrass juice supplement in colon cancer patients during adjuvant chemotherapy. Front Oncol, 2020; 10:1659.
10.
Bar-SelaG, CohenI, AvisarA, et al.Circulating blood extracellular vesicles as a tool to assess endothelial injury and chemotherapy toxicity in adjuvant cancer patients. PLoS One, 2020; 15:e0240994.
11.
TzoranI, Rebibo-SabbahA, BrennerB, et al.Disease dynamics in patients with acute myeloid leukemia: new biomarkers. Exp Hematol, 2015; 43:936–943.
12.
KouL, YaoQ, ZhangH, et al.Transporter-targeted nano-sized vehicles for enhanced and site-specific drug delivery. Cancers (Basel), 2020; 12:2837.
13.
AwasthiR, RosebladeA, HansbroPM, et al.Nanoparticles in cancer treatment: opportunities and obstacles. Curr Drug Targets, 2018; 19:1696–1709.
14.
KhawarMB, AbbasiMH, SiddiqueZ, et al.An update on novel therapeutic warfronts of extracellular vesicles (EVs) in cancer treatment: where we are standing right now and where to go in the future. Oxid Med Cell Longev, 2019; 2019:9702562.
15.
GimonaM, PachlerK, Laner-PlambergerS, et al.Manufacturing of human extracellular vesicle-based therapeutics for clinical use. Int J Mol Sci, 2017; 18:1190.
16.
RohdeE, PachlerK, GimonaM. Manufacturing and characterization of extracellular vesicles from umbilical cord-derived mesenchymal stromal cells for clinical testing. Cytotherapy, 2019; 21:581–592.
17.
KamerkarS, LeBleuVS, SugimotoH, et al.Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature, 2017; 546:498–503.
18.
ChengQ, ShiX, HanM, et al.Reprogramming exosomes as nanoscale controllers of cellular immunity. J Am Chem Soc, 2018; 140:16413–16417.
19.
WangG, HuW, ChenH, et al.Cocktail strategy based on NK cell-derived exosomes and their biomimetic nanoparticles for dual tumor therapy. Cancers (Basel), 2019; 11:1560.
20.
FuW, LeiC, LiuS, et al.CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun, 2019; 10:4355.
21.
StancovskiI, HurwitzE, LeitnerO, et al.Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A, 1991; 88:8691–8695.
22.
EshharZ, WaksT, BendavidA, et al.Functional expression of chimeric receptor genes in human T cells. J Immunol Methods, 2001; 248:67–76.
23.
Globerson LevinA, Rawet SlobodkinM, WaksT, et al.Treatment of multiple myeloma using chimeric antigen receptor T cells with dual specificity. Cancer Immunol Res, 2020; 8:1485–1495.
24.
JamalyS, RambergC, OlsenR, et al.Impact of preanalytical conditions on plasma concentration and size distribution of extracellular vesicles using Nanoparticle Tracking Analysis. Sci Rep, 2018; 8:17216.
25.
ZarfatiM, AviviI, BrennerB, et al.Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis. Angiogenesis, 2019; 22:185–196.
26.
Globerson-LevinA, WaksT, EshharZ. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther, 2014; 22:1029–1038.
27.
Yanez-MoM, SiljanderPR, AndreuZ, et al.Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles, 2015; 4:27066.
28.
YangP, CaoX, CaiH, et al.The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cell Immunol, 2021; 360:104262.
29.
MajchrzakK, NelsonMH, BaileySR, et al.Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother, 2016; 65:247–259.
30.
WagnerJ, WickmanE, DeRenzoC, et al.CAR T cell therapy for solid tumors: bright future or dark reality?. Mol Ther, 2020; 28:2320–2339.
31.
DeshmukhSK, SrivastavaSK, PoosarlaT, et al.Inflammation, immunosuppressive microenvironment and breast cancer: opportunities for cancer prevention and therapy. Ann Transl Med, 2019; 7:593.
32.
AndreuZ, Yanez-MoM. Tetraspanins in extracellular vesicle formation and function. Front Immunol, 2014; 5:442.
KucharzewskaP, ChristiansonHC, WelchJE, et al.Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A, 2013; 110:7312–7317.
35.
ShomerE, KatzenellS, ZiporiY, et al.Microvesicles of women with gestational hypertension and preeclampsia affect human trophoblast fate and endothelial function. Hypertension, 2013; 62:893–898.
36.
RousalovaI, KrepelaE. Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol, 2010; 37:1361–1378.
37.
MardomiA, AbediankenariS. Matrix metalloproteinase 8: could it benefit the CAR-T cell therapy of solid tumors?—a—commentary on therapeutic potential. Cancer Microenviron, 2018; 11:93–96.
38.
BrudnoJN, KochenderferJN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood, 2016; 127:3321–3330.
39.
MurthyH, IqbalM, ChavezJC, et al.Cytokine release syndrome: current perspectives. Immunotargets Ther, 2019; 8:43–52.
40.
ShiY, LiuCH, RobertsAI, et al.Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res, 2006; 16:126–133.
41.
KuehnemuthB, PisedduI, WiedemannGM, et al.CCL1 is a major regulatory T cell attracting factor in human breast cancer. BMC Cancer, 2018; 18:1278.
42.
HiltbrunnerS, LarssenP, EldhM, et al.Exosomal cancer immunotherapy is independent of MHC molecules on exosomes. Oncotarget, 2016; 7:38707–38717.
43.
WiklanderOP, NordinJZ, O'LoughlinA, et al.Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles, 2015; 4:26316.
44.
YuanaY, BoingAN, GrootemaatAE, et al.Handling and storage of human body fluids for analysis of extracellular vesicles. J Extracell Vesicles, 2015; 4:29260.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
